bevacizumab,atezolizumab
roche
['atezo', 'imbrave050', 'hcc']
imbrave050 showed there were no qol differences in those receiving adjuvant atezo/bev vs soc for resected hcc. but is their original primary endpoint of rfs the right one in this disease? could the trial have been designed with os in mind? #asco23 
Dad/hubby|PhD|Med onc@Nepean|@MOGA_ORG Chair|USyd Lecturer|Interests: GI/lung cancer|value|decision making|fin tox|Luv the Rabbitohs & Dr Who|Opinions = mine